Choosing to participate in a clinical trial is an important personal decision. Carefully
conducted clinical trials are the fastest and safest way to find whether new
drugs or treatments are both safe and effective. Participants in clinical trials
can play a more active role in their own health care, gain access to new research
treatments before they are widely available, and help others by contributing
to medical research. All clinical trials have guidelines about who can participate.
Researchers use protocols with defined criteria to identify appropriate participants
and maintain safety standards. For commonly asked questions about clinical trials,
see www.clinicaltrials.gov
We welcome your inquiries about our clinical trials. If you would like more
information or are interested in joining a clinical trial, please contact the
research nurse listed at the Clinical Protocol Office at (919) 966-4432 or toll
free at 1-877-668-0683.
Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in
Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer
Maureen Tynan, RN, OCN®
A6181040
A Phase II Efficacy and Safety Study of SU011248 in Patients
with Metastatic Non-Small Cell Lung Cancer
Tammy Allred, RN, OCN®
RTOG 0214
A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients
with Locally Advanced Non-Small Cell Lung Cancer
Tammy Allred, RNC, OCN®
LCCC 0409
Treatment of Brain Metastases from Non-Small Cell Lung Cancer with Concurrent Whole
Brain Radiation Therapy and Pemetrexed
Maureen Tynan, RN, OCN®
CALGB 30406
A Phase II Randomized Study of OSI-774 (Erlotinib) with or without Carboplatin/Paclitaxel
in Patients with Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light
Smokers
Maureen Tynan, RNC, OCN®
EMD 72000-031
Randomized, Phase II, Open-Label Controlled Study of Two Different
Doses and Schedules of EMD 72000 (matuzumab) in combination with Pemetrexed,
or Pemetrexed alone, as Second-Line Treatment in Subjects with Stage IIIB/IV
Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line
Treatment with a Platinum Analogue in Combination with Either Taxanes or
Gemcitabine
Tammy Allred, RNC, OCN®
C05002
A Multi-center, Open-label, Phase II Study of VELCADE (bortezomib) for Injection
in Previously Treated Patients with Stage IIIb and IV Bronchioloalveolar Carcinoma and Adenocarcinoma
with Bronchioloalveolar Features
Tammy Allred, RNC, OCN®
LCCC 0511
Phase I/II Trial of Induction Carboplatin/Paclitaxel with Bevacizumab followed by
Concurrent Thoracic Conformal Radiation Therapy with Carboplatin/Paclitaxel, Bevacizumab and Erlotinib
in Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Maureen Tynan, RNC, OCN®
LCCC 0512
Randomized Phase II Study of First-Line Treatment with Gemcitabine vs. Erlotinib
vs. Gemcitabine and Erlotinib in Elderly Patients with Stage (IIIB/IV) Non-Small Cell Lung Cancer
